References
- Pratt C B, Roberts D, Shanks E, Warmath E L, Jackson R. Asparaginase in combination chemotherapy for remission induction of childhood acute lymphocytic leukemia. Cancer Res 1973; 33(9)2020–2025
- zur Stadt U, Harms D O, Schluter S, Jorch N, Spaar H J, Nurnberger W, et al. Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase. Klin Padiatr 2000; 212(4)169–173
- Muller H J, Beier R, Loning L, Blutters-Sawatzki R, Dorffel W, Maass E, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001; 114(4)794–799
- Woo M H, Hak L J, Storm M C, Evans W E, Sandlund J T, Rivera G K, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12(10)1527–1533
- Albertsen B K, Schroder H, Jakobsen P, Avramis V I, Muller H J, Schmiegelow K, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002; 38(5)310–316
- Zalewska-Szewczyk B, Andrzejewski W, Młynarski W, Jędrychowska-Dańska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with l-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007; 48: 931–936
- Woo M H, Hak L J, Storm M C, Sandlund J T, Ribeiro R C, Rivera G K, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18(7)1525–1532
- Panosyan E H, Seibel N L, Martin-Aragon S, Gaynon P S, Avramis I A, Sather H, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004; 26(4)217–226